Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
Study Number: Connect Myeloid
Study Summary:
The purpose of the Connect® Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. This disease registry will also evaluate molecular and cellular markers that may provide further prognostic classification which may or may not be predictive of therapy and clinical outcomes.
Status: Open
Enrolling cohorts: newly diagnosed low risk MDS, Treated low risk-MDS, Treated MF, Treated MF cytopenias – includes CMML, aCML, MDS/MPN-RS-T, MDS/MPN unclassifiable
Study Coordinator(s)
- Navigator Heather, 309-243-3661 hthulean@illinoiscancercare.com
- Hannah, 309-243-3628 hknight@illinoiscancercare.com
